Standard BioTools Inc. LAB

Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture’s Unsolicited Acquisition Proposal as SuperiorBOSTON, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”): Standard BioTools terminated its previously an

BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026. Recent Highlights: Second quarter 2026 revenue of $20.1 million1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-yearMerger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026 “We remain on track to close our merger

Standard BioTools (LAB) said Tuesday that it has agreed to sell its Mass Cytometry business to Multi

Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) ("Standard BioTools" or the "Company") today an

BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after U.S. market close.About Standard BioTools Inc. Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes

Highlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts Includes headline Phase 1 monotherapy data for TLN-121 in relapsed or refractory lymphomas with overall response rate of 84%, complete response rate of 32% and no observed dose-limiting toxicities Sue Desmond-Hellmann, renowned industry veteran, joined Treeline’s Boa

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June 17, 2026, at 12:00 PM PT / 3:00 PM ET, featuring President and CEO Roger Moss and moderated by Cory Fleck of the KE Report. The webinar will provide investors with an in-depth overview of the Company's recently acquired Mariposa Gold Project, including its strategic location within the Yukon's prol

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.

Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates Company to be led by Treeline CEO and co-founder Josh Bilenker, MD, and experienced team of proven drug developers Treeline’s pipeline includes three Phase 1 programs with multiple anticipated clinical data readouts beginning in 2027 Well capitalized with over $900 million in cash expected at closing, providing runway into 20

BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026. Recent Highlights: First quarter 2026 revenue of $21.1 million54% reduction in operating loss and 78% improvement in adjusted EBITDA year-over-year supporting path to positive adjusted EBITDA exiting 2026$524 million in cash & investments as of March 31, 2026, excluding $25 million earnout received afte

BOSTON, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. About Standard BioTools Inc. Standard BioTools Inc. (NASDAQ: LAB), has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and

Standard BioTools Inc. (NASDAQ:LAB) is one of the 8 Best Life Sciences Penny Stocks to Buy. As of the April 8 close, Standard BioTools Inc. (NASDAQ:LAB) had a neutral consensus sentiment. The stock received 2 Hold ratings from analysts, with a projected median 1-year price target of $1.35. This yields an impressive upside potential of […]

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational technology.

This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

TORONTO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on Tuesday, February 24, 2026, at 11:00 A.M. (Toronto Time) at Gardiner Roberts LLP, Bay Adelaide Centre, East Tower, 22 Adelaide Street West, Suite 3600, Toronto, Ontario, M5H 4E3 (the “Meeting”). A total of 83,756,898 Common Shares of the Corporation (“Common Shares”) representin

TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Corporation”) is pleased to announce the results of its Annual General and Special Meeting of Shareholders held on Tuesday, February 24, 2026, at 11:00 A.M. (Toronto Time) at Gardiner Roberts LLP, Bay Adelaide Centre, East Tower, 22 Adelaide Street West, Suite 3600, Toronto, Ontario, M5H 4E3 (the “Meeting”). A total of 83,756,898 Common Shares of the Corporation (“Common Shares”) representin